From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 4 June

Jessica Amir
June 4, 2021

Morning Bell 4 June

Sophia Mavridis
June 4, 2021

Morning Bell 3 June

Jessica Amir
June 3, 2021

Morning Bell 2 June

Jessica Amir
June 2, 2021

Morning Bell 1 June

Paulina Peters
June 1, 2021

Morning Bell 31 May

Paulina Peters
May 31, 2021

Weekly Wrap 28 May

Jessica Amir
May 28, 2021

Morning Bell 28 May

Sophia Mavridis
May 28, 2021

Morning Bell 27 May

Paulina Peters
May 27, 2021

Morning Bell 26 May

Jessica Amir
May 26, 2021

Morning Bell 25 May

Jessica Amir
May 25, 2021